Literature DB >> 6731680

The prevalence of human melioidosis in Northern Queensland.

L R Ashdown, R W Guard.   

Abstract

Sera from 9,047 individuals from Northern Queensland were examined for the presence of hemagglutinating antibodies to Pseudomonas pseudomallei, the causative agent of melioidosis, and 512 (5.7%) were found to have titers of 1:40 or greater. The distribution of positive reactors in various groups was uneven, and significantly higher prevalences of positive antibody titers were found in the sera from Aborigines (7.9-10.6%), Torres Strait Islanders (7.8%), Vietnamese refugees (29%) and from persons with certain medical conditions including chronic alcoholism (15%), chronic infections (14.8%), diabetes mellitus (8.6%) and liver disease (12.9%). There were significantly fewer positive reactors (1.4%) amongst the armed forces stationed in Northern Queensland. At present, the boundaries of the major endemic region of Australia extend north from Rockhampton along the coast to Darwin and inland, west from Rockhampton to Tennant Creek in central Australia. Townsville was found to have the highest prevalence (5.2%) of positive reactors of all urban populations of Northern Queensland. The extent of the disease is such that it can no longer be considered a rare infection in Northern Queensland.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6731680     DOI: 10.4269/ajtmh.1984.33.474

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  27 in total

1.  Comparison of automated and nonautomated systems for identification of Burkholderia pseudomallei.

Authors:  Peter Lowe; Catherine Engler; Robert Norton
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

2.  Reactivation of latent melioidosis.

Authors:  A B Johnson; N Ali
Journal:  Postgrad Med J       Date:  1990-09       Impact factor: 2.401

Review 3.  Environmental factors that affect the survival and persistence of Burkholderia pseudomallei.

Authors:  Timothy J J Inglis; Jose-Luis Sagripanti
Journal:  Appl Environ Microbiol       Date:  2006-09-15       Impact factor: 4.792

4.  Role of reactive nitrogen and oxygen intermediates in gamma interferon-stimulated murine macrophage bactericidal activity against Burkholderia pseudomallei.

Authors:  K Miyagi; K Kawakami; A Saito
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

5.  Use of antigens derived from Burkholderia pseudomallei, B. thailandensis, and B. cepacia in the indirect hemagglutination assay for melioidosis.

Authors:  Glenda Gilmore; Jodie Barnes; Natkunam Ketheesan; Robert Norton
Journal:  Clin Vaccine Immunol       Date:  2007-09-05

6.  Multicenter prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis.

Authors:  M Sookpranee; P Boonma; W Susaengrat; K Bhuripanyo; S Punyagupta
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

7.  Evaluation of Culture Techniques for Isolation of Pseudomonas pseudomallei from Soil.

Authors:  L R Ashdown; S G Clarke
Journal:  Appl Environ Microbiol       Date:  1992-12       Impact factor: 4.792

8.  Surprisingly low seroprevalence of Burkholderia pseudomallei in exposed healthy adults in the Darwin region of tropical Australia where melioidosis is highly endemic.

Authors:  Gemma L James; Ben Delaney; Linda Ward; Kevin Freeman; Mark Mayo; Bart J Currie
Journal:  Clin Vaccine Immunol       Date:  2013-03-27

9.  Evidence of Burkholderia pseudomallei-specific immunity in patient sera persistently nonreactive by the indirect hemagglutination assay.

Authors:  Patrick N A Harris; Natasha L Williams; Jodie L Morris; Natkunam Ketheesan; Robert E Norton
Journal:  Clin Vaccine Immunol       Date:  2011-06-15

Review 10.  Clinical features and epidemiology of melioidosis pneumonia: results from a 21-year study and review of the literature.

Authors:  Ella M Meumann; Allen C Cheng; Linda Ward; Bart J Currie
Journal:  Clin Infect Dis       Date:  2011-11-04       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.